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Epstein–Barr virus (EBV) is a herpesvirus associated with lymphomas and carcinomas. While
EBV-associated epithelial cell lines are good model systems to investigate the role of EBV in
carcinoma, only a few cell lines are available as they are hard to acquire. A greater variety of
naturally EBV-infected cell lines which are derived from tumour patients are needed to represent
various features of EBVaGC. We characterized cell line YCCEL1, established from a Korean
EBVaGC patient, to ascertain whether it can be used to study the roles of EBV in EBVaGC. The
expression of EBV genes and cell surface markers was examined by in situ hybridization, RT-PCR,
Western blot analysis, immunofluorescence assay and Northern blot analysis. EBV episomal
status was analysed by Southern blotting and real-time PCR. This cell line expressed EBV nuclear
antigen 1 (EBNA1) and latent membrane protein 2A (LMP2A), but not EBNA2, LMP2B nor LMP1.
The majority of the lytic proteins were not detected in YCCEL1 cells either before or after
treatment with 12-O-tetradecanoylphorbol-13-acetate. YCCEL1 cells expressed BART
microRNAs (miRNAs) at high level but did not express BHRF1 miRNAs. YCCEL1 cells expressed
cytokeratin, but not CD21 and CD19, suggesting CD21-independent EBV infection. The latent
EBV gene and EBV miRNA expression pattern of YCCEL1 cells closely resembled that of general
EBVaGC cases. Our results support the value of YCCEL1 cells as a good model system to study
the role of EBV in gastric carcinogenesis.
INTRODUCTION
Epstein–Barr virus (EBV) is a herpesvirus that infects more
than 90% of the world’s adult population. EBV is associated
with Burkitt’s lymphoma (BL), Hodgkin’s disease, gastric
carcinoma (GC), nasopharyngeal carcinoma (NPC), NK/T
cell lymphoma and post-transplant lymphoproliferative
disorder (Middeldorp et al., 2003; Miller & Lipman, 1973;
Miller et al., 1969). Approximately, 10% of global GC cases
are EBV-associated (Middeldorp et al., 2003; Takada, 2000).
Infection of B lymphocytes by EBV is mediated by the
interaction of viral glycoprotein gp350 with EBV receptor
CD21 expressed on the surface of B-cells (Nemerow et al.,
1987). The mechanism of EBV infection for epithelial cells
that lack CD21 expression is unclear (Young & Rickinson,
2004).
EBV-associated carcinoma cell lines would serve as good
model systems to study the role of EBV in carcinoma.
However, EBV-infected epithelial cell lines are hard to
acquire as, in vitro, EBV infection of epithelial cells is more
complex than that of B-cells (Shannon-Lowe et al., 2006;
Takada, 2000). Furthermore, EBV-infected NPC cells tend
to lose the EBV genome during passages in vitro (Danve
et al., 2001; Teramoto et al., 2000).
EBV-positive GC cell lines reported so far include KT
(Iwasaki et al., 1998), GT38, GT39 (Takasaka et al., 1998),
AGS-EBV-GFP (Tajima et al., 1998) and SNU-719 (Oh et al.,
2004; Park et al., 1997). KT is a transplantable human EBV-
associated GC (EBVaGC) that can be continuously passaged
through severe combined immunodeficient (SCID) mice
(Iwasaki et al., 1998). It is useful to study the role of EBV in a
whole body system, but the cells cannot be cultured,
hindering in vitro experiments. GT38 and GT39 are derived
from the normal tissues of EBVaGC patients. These cells
show latency III as they express EBV nuclear antigen 1
(EBNA1), EBNA2, latent membrane protein 1 (LMP1), Z
EBV replication activator (ZEBRA5Zta5BZLF1) and early3These authors contributed equally to this work/paper.
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antigen-diffuse (EA-D). Thus, the latency type of GT38 and
GT39 cells differs from that of most EBVaGC, which show
modified latency I with EBNA1 and LMP2A expression
(Takasaka et al., 1998).
AGS-EBV-GFP is a GC cell line infected with a recombin-
ant EBV, which displays similar latency to that of general
EBVaGC (Yoshiyama et al., 1997). AGS-EBV-GFP is a
valuable model system as it can be paired with AGS to
clarify the role of EBV infection in GC (Shimizu et al.,
1996; Yoshiyama et al., 1995). One caveat is that this cell
line is established by artificially infecting an EBV-negative
AGS GC cell line with a recombinant EBV originated from
a BL cell line.
SNU-719 is established from EBVaGC tissue and expresses
EBNA1 and LMP2A, but not LMP1 and EBNA2, showing
similar latency to general EBVaGC; it can serve as a good
model for EBVaGC (Oh et al., 2004). More diverse EBV-
infected GC cell lines naturally infected with EBV, such as
SNU-719, are needed for research concerning the various
features of EBVaGC.
In this study, we report the identification and character-
ization of YCCEL1, a GC cell line established from a
Korean EBVaGC patient through natural infection by EBV.
The YCCEL1 cell line could serve as a useful model for
EBVaGC research.
RESULTS
Detecting EBV in YCCEL1
To confirm the infection of EBV at a single-cell level, YCCEL1
cells were analysed by in situ hybridization for EBV encoded
RNA (EBER) expression. Staining of EBER in the nuclei of the
EBV-positive B95-8 cells and YCCEL1 cells confirmed the
presence of EBERs, while EBV-negative BJAB cells did not
show any staining (Fig. 1a). PCR was carried out with unique
primers that could detect PCR products of different sizes for
EBNA2, EBNA3A and EBNA3C to distinguish two different
EBV types: types 1 and 2. The sizes of the PCR products
detected in YCCEL1 cells were the same as those in AGS-
EBV-GFP, SNU-719 and Namalwa cells, which are infected
with type 1 EBV (Fig. 1b).
Expression of EBV latent genes
Western blot analysis, immunofluorescence assay and RT-
PCR were used to investigate the latency of EBV in
YCCEL1 cells. EBV-negative BJAB cells and AGS cells did
not show any sign of EBV latent gene expression, whereas
the latency III EBV (+) lymphoblastoid cell line, SNU-
1103, expressed EBNA1, EBNA2, LMP1, LMP2A and
LMP2B (Fig. 2a, b). We are not sure why multiple bands
were detected in some cell lines using mAb OT1X against
EBNA1. Some of them may be non-specific bands or
modified or degraded EBNA1. The latency III EBV (+)
Burkitt’s lymphoma cell line, Namalwa, also expressed
EBNA1 and EBNA2, but not LMP1 (Fig. 2a). The EBV
gastric cancer cell lines AGS-EBV-GFP and SNU-719
expressed EBNA1 and LMP2A, but not EBNA2 and
LMP1 (Fig. 2a, b). LMP2B was not detectable in YCCEL1
and SNU-719, unlike in AGS-EBV-GFP, which showed
low-level expression of LMP2B mRNA (Fig. 2b). The
expression patterns of latent genes in YCCEL1 cells were
similar to those seen in the EBV-positive gastric cancer cell
line SNU-719 (Fig. 2a–c). The EBV promoter used in
YCCEL1 cells was identified by RT-PCR using specific
primers for each of the three latent promoters of EBV. Cp
or Wp transcripts were detected in the latency III cell lines
Mutu III and Namalwa. In contrast, Qp transcripts were
detected in YCCEL1 cells and in the EBV-positive GC cell
lines AGS-EBV-GFP and SNU-719 (Fig. 2d).
Expression of EBV lytic genes
The effect of TPA on the induction of EBV lytic genes was
analysed in YCCEL1 cells. B95-8 and SUN-719 were used for
comparison and BJAB was used as a negative control. RT-
PCR was performed for 30 cycles and the products were
analysed by agarose gel electrophoresis (Fig. 3a). BZLF1
mRNA was shown at a low level in unstimulated B95-8 cells
and increased dramatically following TPA treatment (Fig.
3a). BZLF1 mRNA expression was undetectable in basal
state SNU-719, but was induced following TPA treatment.
In YCCEL1, no (on 50% of occasions) or a very small
amount of BZLF1 mRNA was detectable without stimu-
lation. TPA treatment caused BZLF1 mRNA expression in
YCCEL1, but the expression level was generally lower than
that observed in SNU-719 (Fig. 3a).
Western blot results showed that the majority of the lytic
proteins were not detectable in YCCEL1 cells even after
TPA treatment (Fig. 3b). This contrasted with the results
for SNU-719 which showed induced lytic protein
expression following TPA treatment. Without TPA
stimulation, immunofluorescence assay showed gp350
expression in 3% of B95-8 cells, but not in SNU-719
and YCCEL1 cells (Fig. 3c). TPA treatment increased
gp350 expression in B95-8 and SNU-719 cells by 40% and
15%, respectively. Rarely (,1%), we detected gp350
expression in YCCEL1 cells.
Clonality of EBV genome and EBV copy numbers
in YCCEL1 cells
To test the clonality of the EBV genome in YCCEL1, DNA
extracted from YCCEL1 cells was digested with BamHI and
Southern blotting was carried out using a DNA probe
specific for the EBV terminal repeat (TR). The TR band
was not detected in the EBV-negative cell line BJAB. The
TR fragments were detected at 21 kb in Raji cells and at
12 kb in SNU-719 cells, while multiple smeared bands at
8–12 kb and 4–6 kb were detected in B95-8 cells. A single
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Fig. 1. Detection of EBV in YCCEL1 cells. (a)
EBER in situ hybridization (ISH). Cells were
fixed and hybridized with an EBER-specific
RNA probe. Positive staining was observed
under a light microscope as dark violet-blue
granules at the site of hybridization (original
magnification: 200). (b) Analysis of EBV type
by PCR. EBNA2-, EBNA3B- and EBNA3C-
specific PCR yielded products with different
sizes depending on the infected EBV type.
Namalwa (type I) and AG876 (type II) were
used as type-specific EBV-positive controls.
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Fig. 2. EBV latent gene expression in YCCEL1
cells. (a) Detection of latent proteins. Cell
lysate was prepared and 50 mg of total cellular
protein from each cell line was analysed by
Western blot using antibody to EBNA1,
EBNA2 or LMP1. Anti-b-actin antibody
(1 : 2000) was used to check the loading
amount. (b) Detection of LMP2A and LMP2B
mRNA. Total RNA was extracted from each
cell line. LMP2A and LMP2B expressions were
analysed by RT-PCR. GAPDH was used as a
loading control. (c) Immunostaining for EBNA1
YCCEL1 cells (original magnification: 200)
and EBV-negative AGS cells were included to
verify specificity of EBNA1 antibody. Cells
were incubated with anti-EBNA1 (OT1X)
antibody. (d) Analysis of latent promoter usage.
A specific 39-primer for each transcript initiat-
ing at the Cp, Wp or Qp EBV promoter was
used for cDNA synthesis. The cDNA was
subjected to latent EBV promoter-specific
PCR. GAPDH mRNA was amplified to com-
pare the quantity and quality of the RNA
samples.
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TR band was detected at 15 kb in YCCEL1 cells (Fig. 4a).
Real-time PCR was carried out for EBNA1 within the EBV
genome to access the EBV copy number in YCCEL1 cells.
The EBV genome was not detected in BJAB cells, which
were used as a negative control, while a very low level of
EBV genome was detected in Namalwa cells. EBV copy
number detected in YCCEL1 cells was similar to that in
SNU-719 cells (Fig. 4b).
No expression of CD21 in YCCEL1 cells
Immunofluorescence assay was used to verify whether
CD21, the receptor for the infection of B-cells by EBV, was
expressed in YCCEL1 cells. CD19 and cytokeratin were
used as markers for B-cells and epithelial cells, respectively.
SNU-719, an EBV-positive gastric epithelial cell line,
expressed cytokeratin, but not CD21 and CD19. BJAB, an
EBV-negative B-cell line, expressed CD21 and CD19, but
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Fig. 3. EBV lytic gene expression in YCCEL1 cells. Cells were treated with TPA (20 ng ml”1) for 4 days to induce the lytic
cycle. (a) RT-PCR analysis of BZLF1 expression. Total cellular RNA was used to access the level of BZLF1 mRNA. EBV-
negative BJAB cells served as a negative control for BZLF1 expression. GAPDH mRNA was amplified to compare the quantity
and quality of the RNA samples. (b) Detection of lytic proteins. Cell lysate was prepared and 30 mg of total cellular protein from
each cell line was analysed by Western blotting using antibodies to BZLF1, BRLF1, BMRF1 or BHRF1. Anti-b-actin antibody
(1 : 2000) was used to check the loading amount. (c) Immounostaining for gp350 in YCCEL1 cells. Expression of gp350 was
detected by incubating with anti-gp350 antibody followed by Cy3-conjugated secondary antibody. B95-8 and SNU-719 was
used as a positive control for gp350 expression. BJAB was used as a negative control (original magnification: 200).
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not cytokeratin. YCCEL1 cells expressed cytokeratin, but
not CD21 and CD19, just like SNU-719 cells (Fig. 5).
Expression pattern of EBV miRNAs in YCCEL1
cells
The expression of EBV BHRF1 miRNAs and BART miRNAs
in YCCEL1 cells was analysed by Northern blotting and
qRT-PCR. YCCEL1 cells expressed higher levels of BART
miRNAs than AGS-EBV-GFP, SNU-719 and SNU-1103 cells
(Fig. 6a, c). The latency III cell lines Namalwa and SNU-
1103 expressed BHRF1 miRNAs, while YCCEL1 cells
together with the latency I cell lines AGS-EBV-GFP and
SNU-719 did not (Fig. 6a). The expression of BART
transcripts in the same cell lines was also analysed by qRT-
PCR (Fig. 6b). As expected, EBV-negative cell lines BJAB
and AGS did not express EBV BART transcripts. In general,
the expression levels of BART transcripts in EBV-positive
cell lines correlated with those of BART miRNAs. However,
the correlation was not very tight as the level of BART
transcript was highest in SNU-719 rather than in YCCEL1
cells, which showed the highest BART miRNA expression
(Fig. 6b).
DISCUSSION
The present results demonstrate the latent EBV infection of
YCCEL1 cells through various analyses. EBV can be
classified as types 1 or 2 according to the differences in
the sequences of its EBNA2 and EBNA3 genes (Sample
et al., 1990). YCCEL1 cells are infected with type I EBV,
similar to the majority of EBV-infected cell lines (Sample
et al., 1990). The latency of EBV-associated malignancies is
classified into three groups according to the EBV gene
expression pattern; these latency patterns are used to
classify the types of EBV-associated cancers (Fukayama
et al., 1998). Namalwa, known as latency I/II, expresses
EBNA1 and EBNA2, but not LMP1 and LMP2 (Bernasconi
et al., 2006; Satoh et al., 2002). Also, we did not detect
LMP2A expression in Namalwa cells by Western blot
analysis, but did detect low levels of LMP2A mRNA by RT-
PCR. The YCCEL1 cell line can be classified as showing
modified latency I because it exhibits a similar pattern to
the naturally EBV-infected EBVaGC cell line SNU-719 (Oh
et al., 2004). Conventional TPA treatment was not efficient
(,1%) at inducing the lytic cycle in YCCEL1 cells, so there
were too few to be detected by Western blot. The
discrepancies between the protein and RNA data for
BZLF1 cells may be due to a sensitivity difference between
the two detection methods.
TRs of the EBV genome are the essential elements for
processing and packaging EBV DNA during genome
circularization (Hammerschmidt & Sugden, 1989). As
established in previous studies, a single TR fragment was
detected at 21 kb in Raji cells and at 12 kb in SNU-719 cells
by Southern blot using a DNA probe specific for EBV TR
(Oh et al., 2004; Raab-Traub & Flynn, 1986). Both
episomal EBV TR bands derived from latent EBV genome
and linear EBV TR bands generated from the lytic EBV
genome were detected in B95-8 cells (Oh et al., 2004). A
single TR band was detected in YCCEL1 cells, indicating
that the YCCEL1 cell line is the result of clonal
proliferation of a single latently EBV-infected cell. Few
YCCEL1 cells undergo the lytic cycle spontaneously,
judging from the fact that only one TR band was observed
by Southern blotting and EBV lytic genes were not
detectable in this cell line at the basal state.
Namalwa cells contain two copies of the EBV genome
integrated into the cellular DNA (Andersson, 1975). In the
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Fig. 4. Analysis of EBV genome in YCCEL1 cells. (a) Detection of
the EBV TR fragment. Thirty micrograms of DNA were digested
with BamHI restriction enzyme, transferred to a membrane and
hybridized with [a-32P] CTP-labelled probes. (b) Quantification of
EBV DNA copies. EBV copy numbers were quantified by real-time
PCR using the EBNA1 Taqman probe. BJAB was used as a
negative control.
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case of B95-8, a proportion of the cells are known to
undergo the lytic cycle under unstimulated conditions, and
this seems to be why multiple fused terminal fragments
were detected in B95-8 cells (Gargouri et al., 2009). The
EBV copy number in YCCEL1 cells was higher than in
Namalwa and Raji cells, and lower than in B95-8 cells. The
EBV copy number in YCCEL1 cells was similar to that in
SNU-719 cells, which is interesting in that both YCCEL1
and SNU-719 are naturally EBV-infected GC cell lines. The
EBV copy number in Raji cells estimated in this study was
higher than that previously reported (Klein et al., 1974).
The infection of B-cells by EBV results from the direct
interaction between EBV gp350/220 and cellular CD21
(Nemerow et al., 1987). However, EBV also infects
epithelial cells that do not express CD21. In these cases,
infection seems to occur through another receptor different
from CD21. Recently, it has been shown that interaction
between gHgL and integrin avb6, avb8 and avb5 can
initiate fusion of EBV with epithelial cells (Chesnokova
et al., 2009). Because YCCEL1 cells do not express CD21,
whereas SNU-719 cells do, these cell lines may be infected
via integrins or another receptor.
SNU-719
CD21
DAPI
DAPI
DAPI
Pancytokeratins
CD19
YCCEL1 BJAB
Fig. 5. Immounostaining for CD21, CD19 and cytokeratin in YCCEL1 cells. SNU-719 was used as a positive control for
cytokeratin expression. BJAB was used as a positive control for CD21 and CD19 expression (original magnification: 400).
D. N. Kim and others
502 Journal of General Virology 94
(a)
(b)
(c)
6
AGS
AGS-EBV-GFP
SNU-719
YCCEL1
5
4
3
2
1
0
1000
100
R
el
at
iv
e 
B
A
R
Ts
 e
xp
re
ss
io
n
R
el
at
iv
e 
m
iR
N
A
 e
xp
re
ss
io
n
10
1
0.1
B
JA
B
A
G
S
S
N
U
-7
19
YC
C
E
L1
N
am
al
w
a
S
N
U
-1
10
3
A
G
S
-E
B
V
-G
FP
B
JA
B
A
G
S
S
N
U
-7
19
YC
C
E
L1
N
am
al
w
a
S
N
U
-1
10
3
A
G
S
-E
B
V
-G
FP
B
JA
B
miR-BHRF1-1
miR-BHRF1-2
miR-BHRF1-3
miR-BART9-3p
miR-BART1-3p miR-BART15-3p miR-BART19-3p
miR-16
U6
miR-BART5-5p
miR-BART7-3p
miR-BART22-3p
miR-16
U6
A
G
S
S
N
U
-7
19
YC
C
E
L1
N
am
al
w
a
S
N
U
-1
10
3
A
G
S
-E
B
V
-G
FP
Fig. 6. Analysis of EBV miRNA expression pattern in YCCEL1 cells. (a) Northern blot analysis of EBV miRNAs; BJAB and AGS
served as negative controls. AGS-EBV-GFP and SNU-719 were used as positive controls for BART miRNAs, while Namalwa
and SNU-1103 were used as positive controls for BHRF1 miRNAs. The U6 snRNA was used as a loading control. The
expression of the cellular miR-16 was assessed as a reference. A large proportion of the RNA from SNU-1103 cells was lost
during the experiments shown on the left panel as noticeable from the miR-16 and U6 bands. (b) Analysis of EBV BART
transcript expression. The expression of BART transcripts in the cells was assayed by qRT-PCR in triplicate. The expression of
BART transcripts was normalized using the expression of GAPDH in each cell line; the results were then expressed relative to
that in Namalwa which showed the lowest BART transcripts. BJAB and AGS served as negative controls. (c) The expression of
miR-BART1-3p, 15-3p and 19-3p was assayed by qRT-PCR in triplicate. Expression of each miR-BART miRNA was first
normalized using that of U6 snRNA in the same cell line; the results were then expressed relative to that in SNU-719.
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YCCEL1 cells did not express BHRF1 miRNA, like AGS-
EBV-GFP and SNU-719 cells. However, the expression of
miR-BART1-3p, 5-5p, 7-3p, 15-3p, 19-3p and 22-3p was
detected in AGS-EBV-GFP, SNU-719 and YCCEL1 cells by
Northern blot and qRT-PCR. The expression pattern of EBV
miRNAs in YCCEL1 cells was similar to that reported in
EBV-associated GC and tissues (Kim et al., 2007). BART
miRNAs were expressed to a greater extent in YCCEL1 cells
than in the other cell lines examined. As the expression levels
of BART miRNAs correlate with that of BART transcripts in
general, BART miRNAs seemed to be expressed more highly
than expected in YCCEL1 cells. The reason for this disparity
is unclear, but it could be due to different processing and/or
stability of miRNAs in different cell lines.
Because the EBV gene expression pattern of YCCEL1 cells
closely resembles that of EBVaGC cases, this naturally
EBV-infected cell line may serve as a valuable model system
to clarify the function of EBV in GC.
METHODS
Establishment of an EBV-infected gastric carcinoma cell line
YCCEL1. The YCCEL1 cell line was established from the ascitic fluid
of a pathologically proven gastric cancer patient, a 64 year-old-
Korean male with advanced gastric cancer with carcinomatosis, and
the biopsy showed poorly differentiated adenocarcinoma. Ascitic fluid
was collected, pelleted, washed and resuspended in minimum
essential medium (MEM) supplemented with 10% heat-inactivated
FBS. Initially, 56105 cells were seeded into 25 cm2 flasks and
adherent cultures were passaged whenever vigorous tumour cell
growth was observed. Subsequent passages were performed weekly
after trypsinization at subconfluence. During the initial culture,
differential trypsinization was used to obtain a pure tumour cell
population when stromal cell growth was noted.
Cell culture. EBV-positive cell lines (AGS-EBV-GFP, SNU-719,
Mutu III, Namalwa, SNU-1103, B95-8, LCL1 and Raji) and EBV-
negative cell lines (BJAB and AGS) were used. The cells were
maintained in RPMI 1640 (Gibco-BRL) supplemented with 10% FBS
and maintained at 37 uC in a 5% CO2 incubator.
RNA and genomic DNA extraction. RNA extraction was conducted
with RNAzol B reagent (Tel-Test) according to the manufacturer’s
instructions. DNA was extracted from the cells by the standard
phenol/chloroform technique. Briefly, for cell lysis, EBV-infected cell
lines were incubated for 15 h at 55 uC with TE buffer (pH 8.0)
containing proteinase K (200 mg ml21) and 0.5% SDS. Genomic
DNA was obtained using phenol/chloroform extraction, and the
aqueous fraction was collected. Genomic DNA was precipitated with
2-propanol and washed with 70% ethanol. The DNA was dried at
room temperature and dissolved in distilled water.
RT-PCR and DNA PCR. First-strand cDNA synthesis was performed
using 1 mg total RNA and a 39-primer specific for each transcript
initiating at the Cp, Wp or Qp EBV promoter. The cDNA samples
were then subjected to PCR using appropriate primer pairs for the
transcripts initiating at the Cp, Wp or Qp (Sugiura et al., 1996). Each
cycle consisted of denaturation for 30 s at 94 uC, annealing for 30 s at
59 uC and extension for 30 s at 72 uC. The PCR products were
electrophoresed in a 1.5% agarose gel (Kim et al., 2011).
Distinguishing between EBV types 1 and 2 was accomplished using
specific PCR primers for EBNA2, EBNA3B and EBNA3C (Oh et al.,
2004). The PCR primer sequences used for LMP2A and LMP2B RT-
PCR were as reported previously (Oh et al., 2004).
In situ hybridization for EBV encoded RNAs. In situ hybridization
was performed using the ZytoFast EBV-CISH system (ZytoVision),
which is designed for the detection of EBERs. The EBER
oligonucleotide probe is directed against EBER-1 and EBER-2 RNA
sequences transcribed in latently EBV-infected cells. Slides were fixed,
predigested by pepsin diluents (5 min, 37 uC) and hybridized with
the EBER oligonucleotide probe tagged with Biotin (1 h, 55 uC).
Alkaline phosphatase-conjugated-streptavidin was then applied for
detection (30 min, 37 uC). Nitro blue tetrazolium chloride/5-bromo-
4-chlor-3-indolyl phosphate, toluidine salt (NBT/BCIP) was used as
chromogen (20–40 min, 37 uC). All slides were kept in a moisture
chamber during the procedures.
Western blot analysis. To detect the expression of EBV lytic genes
in various cell lines, anti-BZLF1 (Dako; 1 : 500), anti-BRLF1 (Argene;
1 : 500), anti-BMRF1 (Novocastra; 1 : 500) and anti-BHRF1 (3E8,
1 : 250) (Chou et al., 2004) antibodies were used. To detect the
expression of EBV latent genes, anti-EBNA1 (gift from Dr Jaap
Middeldorp, VU University Medical Center, The Netherlands;
1 : 1000), anti-EBNA2 (Dako; 1 : 500) and anti-LMP1 (Dako; 1 : 500)
antibodies were used. Anti-b-actin (Cell Signalling Technologies;
1 : 2000) antibody was also used to confirm comparable loading.
Immunofluorescence assay. Cells were harvested and attached to
12-well multi-test slides. After the cells had been fixed with 4%
paraformaldehyde, they were blocked with 20% normal goat serum.
The cells were incubated with anti-EBNA1 (1 : 100) antibodies.
Following incubation with Cy3-labelled secondary antibody, the slides
were treated with 49,6-diamidino-2-phenylindole (DAPI) mounting
solution (Invitrogen). Protein expression was observed using an
Axiovert 200 fluorescence microscope (Carl Zeiss).
To detect expression of EBV lytic genes, cells were treated with
20 ng ml21 of 12-O-tetradecanoylphorbol-13-acetate (TPA) for
4 days before experiments. The cells were harvested and attached to
12-well multi-test slides. To detect expression of CD21, CD19 and
cytokeratins, cells were cultured in eight-well chamber slides. Cells
were fixed with 100% ice-cold acetone. After blocking with 20%
normal goat serum, cells were incubated with anti-gp350 (Chemicon;
1 : 200), anti-CD21 (Abcam; 1 : 200), PE-conjugated anti-CD19
(BioLegend; 1 : 100) and anti-pancytokeratin (Invitrogen; 1 : 200)
antibodies. Following incubation with Cy3-labelled secondary anti-
body, slides were treated with DAPI-mounting solution (Invitrogen).
Protein expression was observed using an Axiovert 200 fluorescence
Microscope (Carl Zeiss).
Southern blot analysis. Purified genomic DNA (30 mg) was digested
for 15 h with BamHI. The digested DNA was separated on a 0.7%
agarose gel and denatured for 30 min in 0.25 N HCl. The DNA was
transferred to a Hybond-N+ membrane (Amersham). The membrane
was pre-hybridized using ExpressHyb Hybridization Solution
(Clontech) with salmon sperm DNA and hybridized at 60 uC for 1 h
with a 32P-labelled specific probe for EBV terminal repeat sequence. After
washing using wash solution containing 26 standard saline citrate and
1% SDS, the membrane was exposed to X-ray film at 270 uC for 4 h.
Quantitative PCR to access EBV genome copies. Genomic DNA
was used for Q-PCR assay to determine the EBV-DNA copy number
per cell. Q-PCR was performed using 200 ng genomic DNA.
Sequences of the EBNA1 primer and Taqman probe used for Q-
PCR were as follows: primer 59-GGATGCGATTAAGGACCTTGTT-
39 and 59-AAAGCTGCACACAGTCACCCT-39, probe 59-FAM-TG-
ACAAAGCCCGCTCCTACCTGCAAT-TAMSp-39. The thermocy-
cling conditions were 45 cycles of 95 uC for 5 s and 55 uC for 25 s
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with an initial cycle of 95 uC for 30 s. Specific product was detected
using the MX-3000P (Stratagene) detector for quantification. EBV
copy numbers were calculated based on the facts that Namalwa cells
have two copies of the EBV genome per cell (Andersson, 1975).
Small RNA extraction and Northern blot analysis. Small RNA was
extracted using a mirVana microRNA Isolation kit (Ambion) according
to the manufacturer’s protocol. For the Northern blot analysis of EBV
miRNA expression, 1 mg small RNA per sample was electrophoresed in
15% polyacrylamide–urea gel and transferred onto a Zeta-Probe
blotting membrane (Bio-Rad Laboratories). Oligonucleotides comple-
mentary to each mature EBV miRNA were end-labelled with [c-32P]
ATP as a probe (Kim et al., 2011). Hybridization was performed in
ExpressHyb hybridization solution (Clontech).
Real-time qPCR for BART transcripts. Total cellular RNA was
reverse-transcribed with random hexamers using the MMLV-RT
system (Invitrogen). The gene-specific primers used were BART 59-
ATGCTGCTGGTGTGCTGTAA-39 and 59-GCGGTGCTATGGACC-
TGTAT-39, GAPDH 59-CATGAGAAGTATGACAACAGCCT-39 and
59-AGTCCTTCCACGATACCAAAGT-39. Quantitative real-time RT-
PCR of BART and GAPDH was carried out on an MX-3000p Real-
Time PCR machine (Agilent Life Sciences) using SYBR Premix Ex
Taq (Tli RNaseH Plus) (Takara Bio).
Real-time qPCR for BART miRNAs. TaqMan microRNA assay
(Applied Biosystems) was used to quantify the relative expression
levels of miR-BART1-3p, miR-BART15-3p, miR-BART19-3p and U6
snRNA, which was used as an internal control. cDNA was synthesized
using a TaqMan microRNA reverse transcription kit. Briefly, for each
7 ml reverse transcription (RT) master mixture, we combined 0.15 ml
100 mM dNTPs, 1 ml MultiScribe reverse transcriptase, 1.5 ml 106
RT buffer, 0.19 ml RNase inhibitor and 4.16 ml nuclease-free water.
The 7 ml RT master mixture was then combined in a fresh tube with
5 ml total RNA (1 ng) and 3 ml RT primer (specific to each TaqMan
assay), and gently mixed. The RT reactions were then performed on a
DNA Engine thermal cycler (Bio-Rad) programmed to incubate the
reactions at 16 uC for 30 min, 42 uC for 30 min and 85 uC for 5 min.
TaqMan qRT-PCRs was carried out a Mx3000P real-time PCR system
(Stratagene). Each qRT-PCR was performed in 20 ml volume,
containing 10 ml TaqMan universal PCR master mix II, 1 ml 206
TaqMan microRNA assay mix, 8 ml RNase-free water and 1 ml single-
stranded cDNA product. Experiments were carried out in triplicate
for each sample. Relative gene expression was calculated according to
the comparative Ct method using U6 snRNA as an internal standard.
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